Netupitant / palonosetron with dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous hematopoietic stem cell transplantation: a single-center experience

   Aim. To assess efficacy of netupitant / palonosetron with dexamethasone for chemotherapy‑induced nausea and vomiting in 20 patients with multiple myeloma who underwent autologous hematopoietic stem cell transplantation.

   Materials and methods. The inclusion criteria were patients aged ≥18 years with a diagnosis of multiple myeloma, eligible for transplantation and a favorable response (according to the International Myeloma working Group criteria after induction therapy). Netupitant / palonosetron was administered at a dose of 1 capsule (300 mg netupitant; 0.5 mg palonosetron) 1 h before the start of chemotherapy conditioning (day –3) and dexamethasone was administered at day – 3 (12 mg), day – 2…0 (8 mg). Intravenous metoclopramide 10 mg was used as a rescue antiemetic when needed. Patients were evaluated every day for up to 12 days after autologous hematopoietic stem cell transplantation. The primary endpoint was the rate of complete response (no emesis and no rescue medication during 120 h after conditioning). Secondary endpoints were defined as the rate of complete response during the acute phase (0–24 h) and delayed phase (25–120 h) from the start of high‑dose melphalan. The safety of combination was also evaluated. 20 patients were included. The median age was 53.5 (37–67) years.

   Results. Netupitant / palonosetron with dexamethasone prophylaxis showed a high efficacy in preventing chemotherapy‑induced nausea and vomiting during the high‑dose melphalan conditioning period. The primary outcome was largely achieved with a complete response observed in 14 (70 %) patients at 120 h. The complete response rate during the acute phase was 70 % (n = 14). during the delayed phase, the complete response rate was 95 % (n = 19). Grade 1 nausea and vomiting were experienced by 70 % of the patients, grade 2 – by 30 % of patients. No patients had grade 3–4 nausea or vomiting. Intravenous metoclopramide 10 mg was used in 30 % (6 patients).

   Conclusion. Firstly in Russia we assess efficacy of netupitant / palonosetron with dexamethasone for chemotherapy‑induced nausea and vomiting in 20 patients with multiple myeloma who received high‑dose melphalan for autologous hematopoietic stem cell transplantation.

1. Child J., Morgan G., Davies F. et al. High­dose chemotherapy with hematopoietic stem­cell rescue for multiple myeloma. N Engl J Med 2003;348(18):1875–83. DOI: 10.1056/NEJMoa022340

2. Larsen J., Nordström G., Ljungman P., Gardulf A. Symptom occurrence, symptom intensity, and symptom distress in patients undergoing high­dose chemotherapy with stem­cell transplantation. Cancer Nurs 2004;27(1):55–64. DOI: 10.1097/00002820­200401000­00007

3. López­-Jiménez J., Martín­-Ballesteros E., Sureda A. et al. Chemotherapy­induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006;91(1):84–91.

4. Dranitsaris G., Molassiotis A., Clemons M. et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy­induced nausea and vomiting. Ann Oncol

5. ;28(6):1260–7. DOI: 10.1093/annonc/mdx100

6. Pastore D., Bruno B., Carluccio P. et al. Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. Ann Hematol 2020;99(6):867–75. DOI: 10.1007/s00277­020­03945­3

7. Navari R. Pathogenesis­based treatment of chemotherapy­induced nausea and vomiting – two new agents. J Support Oncol 2003;1(2):89–103.

8. Bayraktar U., Bashir Q., Qazilbash M. et al. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19(4):344–56. DOI: 10.1016/j.bbmt.2012.08.011

9. D’Souza A., Fretham C., Lee S. et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant 2020;26(10):e177–82. DOI: 10.1016/j.jtct.2021.02.006

10. Passweg J., Baldomero H., Chabannon C. et al. The EBMT activity survey on hematopoietic­cell transplantation and cellular therapy 2018: CAR­T’s come into focus. Bone Marrow Transplant

11. ;55(11):1604–13. DOI: 10.1038/s41409­020­0826­4

12. Giralt S. 200 mg/m2 melphalan – the gold standard for multiple myeloma. Nat Rev Clin Oncol 2010;7(8):490–1. DOI: 10.1038/nrclinonc.2010.104

13. Martino M., Olivieri A., Ofdani M. et al. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell

14. transplantation in multiple myeloma. Expert Opin Investig Drugs 2013;22(6):619–34. DOI: 10.1517/13543784.2013.788643

15. Tendas A., Marchesi F., Mengarelli A. et al. Prevention of chemotherapy­induced nausea and vomiting after high­dose melphalan and stem cell transplantation: review of the evidence and suggestions. Support Care Cancer 2019;27(4):793–803. DOI: 10.1007/s00520­018­4594­2

16. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Antiemesis. Version 2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf

17. Jordan K., Jahn F., Jahn P. et al. The NK­1 receptor­antagonist aprepitant in high­dose chemotherapy (high­dose melphalan and high­dose T­ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 2011;46(11):784–9. DOI: 10.1038/bmt.2010.205

18. Musso M., Scalone R., Crescimanno A. et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high­dose chemotherapy with auto­SCT. Bone Marrow Transplant 2010;45(2):123–7. DOI: 10.1038/bmt.2009.114

19. Triflio S., Welles C., Seeger K. et al. Olanzapine reduces chemotherapy­induced nausea and vomiting compared with aprepitant in myeloma patients receiving high­dose melphalan before stem cell transplantation: a retrospective study. Clin Lymphoma Myeloma Leuk 2017;17(7):584–9. DOI: 10.1038/bmt.2009.114

20. Bechtel T., McBride A., Crawford B. et al. Aprepitant for the control of delayed nausea and vomiting associated with the use of high­dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer 2014;22(11):2911–6. DOI: 10.1007/s00520­014­2248­6

21. Deauna­Limayo D., Aljitawi O., Ganguly S. et al. Combined use of multiday palonosetron with aprepitant and low­dose dexamethasone in prevention of nausea and emesis among patients

22. with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: a pilot study. J Oncol Pharm Pract 2014;20(4):263–9. DOI: 10.1177/1078155213502103

23. Aapro M., Rugo H., Rossi G. et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed­dose combination of netupitant and palonosetron, for prevention of chemotherapy­induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014;25(8):1328–33. DOI: 10.1093/annonc/mdu101

24. Hesketh P., Rossi G., Rizzi G. et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy­induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose­ranging pivotal study. Ann Oncol 2014;25(7):1340–6. DOI: 10.1093/annonc/mdu110

25. Di Renzo N., Musso M., Scimè R. et al. Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple­day and high­dose

26. chemotherapy in patients with non-­Hodgkin’s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. Bone Marrow Transplant 2020;55(11):2114–20. DOI: 10.1038/s41409­020­0909­2

27. Apolito V., Giaccone L., Ferrero S. et al. Netupitant­palonosetron to prevent chemotherapy­induced nausea and vomiting in multiple myeloma patients receiving high­dose melphalan and autologous stem cell transplantation. Ann Hematol 2020;99(12):2197–9. DOI: 10.1007/s00277­020­04180­6

28. Loteta B., Paviglianiti A., Naso V. et al. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high­dose melphalan

29. for autologous stem cell transplantation: a single­center experience. Support Care Cancer 2022;30:585–91. DOI: 10.1007/s00520­021­06472­7

30. Tendas A., Niscola P., Perrotti A. et al. Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need. Support Care Cancer 2015;23(10):2211. DOI: 10.1007/s00520­015­2711­z

31. Tendas A., Sollazzo F., Bruno A. et al. Obstacles to managing chemotherapy­-induced nausea and vomiting in high­dose chemotherapy with stem cell transplant. Support Care Cancer

32. ;20(7):891–2. DOI: 10.1007/s00520­012­1411­1

33. Razvi Y., Chan S., McFarlane T. et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy­induced nausea and vomiting in adult patients. Support Care Cancer 2019;27(1):87–95. DOI: 10.1007/s00520­018­4464­y

34. Isoda A., Saito R., Komatsu F. et al. Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study. Int J Hematol 2017;105(5):478–84. DOI: 10.1007/s12185­016­2152­6

35. Giralt S.A., Mangan K.F., Maziarz R.T. et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high­dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 2011;22(6):939–46. DOI: 10.1093/annonc/mdq457

36. Mirabile A., Celio L., Magni M. et al. Evaluation of an every­other­ day palonosetron schedule to control emesis in multiple­day high-dose chemotherapy. Future Oncol 2014;10(18):2569–78.

37. DOI: 10.2217/fon.14.132

38. Uchida M., Ikesue H., Miyamoto T. et al. Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high­dose chemotherapy prior to autologous hematopoietic stem cell

39. transplantation. Biol Pharm Bull 2013;36(6):819–24. DOI: 10.1248/bpb.b12­01012

40. Schmitt T., Goldschmidt H., Neben K. et al. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high­dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo­controlled phase III trial. J Clin Oncol 2014;32(29):3413–20. DOI: 10.1200/JCO.2013.55.0095

41. Clark S., Clemmons A., Schaack L. et al. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high­dose melphalan before autologous hematopoietic

42. stem cell transplant. J Oncol Pharm Pract 2016;22(5):416–22. DOI: 10.1177/1078155215585190

43. Gonullu G., Demircan S., Demirag M.K. et al. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 2012;20(10):1435–9. DOI: 10.1007/s00520­011­1226­5

44. Decramer M., Lacquet L.M., Fagard R., Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994;150(1):11–6. DOI: 10.1164/ajrccm.150.1.8025735

45. Schakman O., Gilson H., Thissen J.P. Mechanisms of glucocorticoid­induced myopathy. J Endocrinol 2008;197(1):1–10. DOI: 10.1677/JOE­07­0606